Memorial Sloan-Kettering medical oncologist Clifford A. Hudis, president elect of the American Society of Clinical Oncology (ASCO) and a renowned leader in practice-changing translational research and clinical care, discusses a number of highlights related to ongoing research in melanoma, includinguveal melanoma.
For more information:
– Ipilimumab + GM-CSF Significantly Improves Survival in Patients With Metastatic Melanoma Compared to Ipilimumab Alone [Read Article]
– Selumetinib Is the First Effective Drug for Advanced Melanoma of the Eye [Read Article]
Advertisement #5
